Thus, research efforts have focused on finding alternative therapies to trastuzumab and lapatinib for the treatment of Her2-positive breast cancer. Efforts aimed at understanding the mechanism of action of trastuzumab and lapatinib and the causes of resistance have led to the identification of several ...
No compatible source was found for this media. Session ID: 2024-12-13:1ca6d7f4b5a557f1e50454e Player Element ID: vjs_video_1241 OK Close Modal Dialog EP: 1.Treatment Options in HER2-Positive Metastatic Breast Cancer EP: 2.Tucatinib for HER2-Positive Metastatic Breast Cancer EP: 3.Update...
“There have been many advances in the development of drugs for HER2-positive breast cancer since the introduction of Herceptin (trastuzumab) in 1998. The approval of Enhertu represents the newest treatment option for patients who have progressed on available HER2-directed therapi...
This study evaluated by immunohistochemistry (IHC) immune cell response during neoadjuvant primary systemic therapy (PST) with trastuzumab in patients with HER2-positive primary breast cancer. In all, 23 patients with IHC 3+ primary breast cancer were treated with trastuzumab plus docetaxel. Pathological...
Cancer Network: Dr. Pegram, what are the current HER2 therapies available for treatment of women with HER2-positive breast cancer? Dr. Pegram: Since 1998, we have had trastuzumab, which has become the mainstay of HER2-targeted breast cancer therapies for both advanced ca...
HER2-positive (HER2+) breast cancer (BC) is a heterogenous and multifaceted disease, with interesting therapeutic implications. First, all intrinsic molecu... FSA B,Aleix Prat a b c d e - 《Breast》 被引量: 0发表: 2021年 How to Optimise Extended Adjuvant Treatment with Neratinib for Patien...
The UK has conditionally approved Enhertu® (trastuzumab deruxtecan) as a monotherapy for the treatment of unresectable or metastatic HER2 positive breast cancer based on Phase II trial results...
Breast Cancer: Targets and Therapy Dovepress open access to scientific and medical research Open Access Full Text Article Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients Review This article was published in the following Dove Press journal: Breast ...
Can we use inhibitors of mutp53 for future treatment Her2-positive breast cancer? Is it important to detect the status of p53 in Her2-positive breast cancer? What approaches should be used to suppress mutp53? Breast cancer classification
continuing trastuzumab beyond progression (TBP) in HER2-positive metastatic breast cancer (MBC) patients, who progressed on first-line trastuzumab, is still unclear. The objective of this population based cohort study was to compare outcomes of lapatinib vs. TBP in daily practice. All HER2-positive...